Impact of pretransplant rifaximin therapy on early post-liver transplant infections

Liver Transplantation

Volumn 20, Issue 5, 2014, Pages 544-551

  Esfeh, Jamak Modaresi ^a   Hanouneh, Ibrahim A ^a   Koval, Christine E ^a   Kovacs, Christopher ^a   Dalal, Deepan S ^a   Ansari Gilani, Kianoush ^a   Confer, Bradley D ^a   Eghtesad, Bijan ^a   Zein, Nizar N ^a   Narayanan Menon, K V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RIFAXIMIN; STEROID; TACROLIMUS; ANTIINFECTIVE AGENT; RIFAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; COHORT ANALYSIS; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MYCOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; VANCOMYCIN RESISTANT ENTEROCOCCUS; AGED; BACTERIAL INFECTIONS; COMPLICATION; LIVER FAILURE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSES; STATISTICAL MODEL;

AGED; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; FEMALE; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; MYCOSES; RETROSPECTIVE STUDIES; RIFAMYCINS;

EID: 84899648301     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23845     Document Type: Article

References (27)

1. Baccarani U, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis 2010; 42: 55-60.
2. Fishman JA,. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614.
3. Razonable RR, Findlay JY, O'Riordan A, Burroughs SG, Ghobrial RM, Agarwal B, et al. Critical care issues in patients after liver transplantation. Liver Transpl 2011; 17: 511-527.
4. San-Juan R, Aguado JM, Lumbreras C, Fortun J, Len O, Munoz P, et al.; for Spanish Network of Infection in Transplantation/Spanish Network for Research in Infectious Diseases. Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation. Liver Transpl 2011; 17: 896-904.
5. Albright JB, Bonatti H, Mendez J, Kramer D, Stauffer J, Hinder R, et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int 2007; 20: 856-866.
6. Dubberke ER, Riddle DJ,; for AST Infectious Diseases Community of Practice. Clostridium difficile in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S35-S40.
7. Garzoni C,; for AST Infectious Diseases Community of Practice. Multiply resistant gram-positive bacteria methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (MRSA, VISA, VRSA) in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S41-S49.
8. Pappas PG, Silveira FP,; for AST Infectious Diseases Community of Practice. Candida in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S173-S179.
9. van Delden C, Blumberg EA,; for AST Infectious Diseases Community of Practice. Multidrug resistant gram-negative bacteria in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S27-S34.
10. Zuckerman R, Wald A,; for AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S104-S107.
11. D'Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A,. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. BMJ 1998; 316: 1275-1285.
12. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PM, Vroom MB, Dankert J, Kesecioglu J,. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003; 362: 1011-1016.
13. Nathens AB, Marshall JC,. Selective decontamination of the digestive tract in surgical patients: a systematic review of the evidence. Arch Surg 1999; 134: 170-176.
14. Krueger WA, Lenhart FP, Neeser G, Ruckdeschel G, Schreckhase H, Eissner HJ, et al. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 2002; 166: 1029-1037.
15. Gorensek MJ, Carey WD, Washington JA II, Vogt DP, Broughan TA, Westveer MK,. Selective bowel decontamination with quinolones and nystatin reduces gram-negative and fungal infections in orthotopic liver transplant recipients. Cleve Clin J Med 1993; 60: 139-144.
16. Rivkin A, Gim S,. Rifaximin: new therapeutic indication and future directions. Clin Ther 2011; 33: 812-827.
17. Belavic JM,. A new use for Xifaxan. Nurse Pract 2011; 36: 8-9.
18. Hong KS, Kim JS,. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol 2011; 4: 227-235.
19. Gruttadauria G, La Barbera F, Cutaia G, Salanitri G,. Prevention of infection in colonic surgery by rifaximin. A controlled, prospective, randomized trial. Riv Eur Sci Med Farmacol 1987; 9: 101-105.
20. Humar A, Michaels M,; for AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
21. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al.; for European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008; 46: 1813-1821.
22. Singh N,. Infectious diseases in the liver transplant recipient. Semin Gastrointest Dis 1998; 9: 136-146.
23. Zwaveling JH, Maring JK, Klompmaker IJ, Haagsma EB, Bottema JT, Laseur M, et al. Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit Care Med 2002; 30: 1204-1209.
24. Hellinger WC, Yao JD, Alvarez S, Blair JE, Cawley JJ, Paya CV, et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 2002; 73: 1904-1909.
25. Barkholt L, Ericzon BG, Tollemar J, Malmborg AS, Ehrnst A, Wilczek H, Andersson J,. Infections in human liver recipients: different patterns early and late after transplantation. Transpl Int 1993; 6: 77-84.
26. Sun HY, Wagener M, Cacciarelli TV, Singh N,. Impact of rifaximin use for hepatic encephalopathy on the risk of early post-transplant infections in liver transplant recipients. Clin Transplant 2012; 26: 849-852.
27. San Juan R, Aguado JM, Lumbreras C, Díaz-Pedroche C, Lõpez-Medrano F, Lizasoain M, et al.; for RESITRA Network, Spain. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7: 964-971.